Hologic, Inc. (NASDAQ:HOLX) Shares Sold by New South Capital Management Inc.

New South Capital Management Inc. lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 0.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 193,679 shares of the medical equipment provider’s stock after selling 840 shares during the quarter. New South Capital Management Inc.’s holdings in Hologic were worth $14,381,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of HOLX. Innealta Capital LLC purchased a new position in shares of Hologic in the 2nd quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new stake in shares of Hologic during the first quarter worth $37,000. Mather Group LLC. purchased a new stake in shares of Hologic during the first quarter valued at $48,000. Massmutual Trust Co. FSB ADV increased its position in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 137 shares during the period. Finally, Toth Financial Advisory Corp raised its stake in Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Activity

In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. Insiders have sold a total of 18,280 shares of company stock worth $1,469,973 over the last 90 days. 1.75% of the stock is currently owned by company insiders.

Hologic Stock Performance

Shares of HOLX stock opened at $81.57 on Friday. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The business’s 50 day moving average is $79.45 and its two-hundred day moving average is $76.64. The company has a market capitalization of $19.04 billion, a P/E ratio of 41.62, a P/E/G ratio of 2.57 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 EPS. Analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HOLX. Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a research note on Tuesday, July 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a report on Friday, August 16th. Evercore ISI lifted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Finally, StockNews.com cut Hologic from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 10th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.